Funding the 3X3 plan

Rather than take advantage of a piping hot IPO market, Melinta Therapeutics Inc. is using last week's private round to extract more value out of its delafloxacin antibiotic. The company plans to focus on three Phase III trials of the molecule before testing the public waters.